Loading
journalsJournal
Cancer Epidemiology, Biomarkers & Prevention
AACR's epidemiology and prevention journal: risk factors, screening, early-detection biomarkers and cancer disparities.
Also called: Cancer Epidemiol Biomarkers PrevCEBP
Overview
Cancer Epidemiology, Biomarkers & Prevention (CEBP) is the epidemiology and prevention journal of the American Association for Cancer Research (AACR), founded in 1991, appearing monthly and published by the society on a hybrid access model. It covers risk factors, screening, early-detection biomarkers and cancer disparities, publishing cohort and case-control studies of cancer risk, biomarker validation for early detection, screening uptake and disparities research, and coverage of the AACR Cancer Disparities Progress Report. Its readers are epidemiologists, prevention researchers and public health specialists. A reader of OnCo would use it for the population evidence on cancer risk, screening and early-detection biomarkers that sits upstream of treatment.
Publisher
American Association for Cancer Research · American Association for Cancer Research
Scope
cancer epidemiology
Website
Access model
hybrid
Founded
1991
ISSN
1055-9965
observationalCancer Epidemiology, Biomarkers & Prevention 2017411 citations
Prevalence and Penetrance of Major Genes and Polygenes for Colorectal Cancer
One bottleneck page on OnCo cites this paper by its DOI; this record gives the citation a page of its own so a reader can follow it without leaving OnCo. Read the abstract above alongside the citing page listed under Related; the record was created automatically from the Europe PMC entry and its figures have not been checked by hand.
meta analysisCancer Epidemiology, Biomarkers and Prevention 2012259 citations
The TMPRSS2-ERG rearrangement, ERG expression and prostate cancer outcomes: a cohort study and meta-analysis
It is the definitive negative result for the commonest genomic alteration in this disease. A man told his tumour carries the TMPRSS2-ERG fusion should be told plainly that it does not make his cancer more dangerous.